Dr Agarwals Health Care Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Strong Quarter with Record Expansion and Double-Digit Growth
Q2 FY27 revenue from operations of Rs.655 crores — up 31.4% YoY and 6.7% QoQ; total income Rs.665 crores (+31.3% YoY).
Q2 FY27 India EBITDA of Rs.143.2 crores at 21.5% margin — per CFO Yashwant Venkat; prior-year Q2 FY26 India EBITDA was Rs.111.2 crores, no prior-year margin disclosed.
Q2 FY27 PAT of Rs.57 crores — up 55.8% YoY with margin at 8.5% (+134 bps).
H1 FY27 revenue from operations of Rs.1,269 crores — up 28.7% YoY (vs Rs.986 crores in H1 FY26); India revenue Rs.1,138 crores (+28.5% YoY), driven by 8% volume and 9.5% value contributions, with the remainder from new centers opened in FY26 and FY27.
H1 FY27 PAT of Rs.112 crores (+50.1% YoY) — margin improved from 7.4% to 8.7%; PBT grew 45.5% to Rs.155 crores; achieved despite startup losses from 50–51 surgical facilities launched over the trailing 12 months.
SSSG of 18.8% in Q2 FY27 — decomposed by the CFO as ~8% volume (OPD growth 7.5% plus conversion 0.5%) and 9.5% value growth, of which premiumization contributed ~8% and 1.5% from "buys".
Record 21 Additions in Q2; FY27 Guidance Raised to 65 Facilities
21 facilities added in Q2 FY27 — 19 greenfield (a highest-ever 18 surgical facilities in a single quarter) plus 2 acquired in Delhi NCR; H1 FY27 additions total 39; India network now 305 facilities across 14 states, 5 UTs and 172 cities (overall network 324).
FY 2026-2027 guidance raised to 65 new facilities — from 60 earlier, including 55 surgical facilities (vs 40 earlier); H2 FY27 plan of 26 additions (21 surgical): South 25, North 20, West 15, East 5. CBO Ashar Agarwal framed this as revising, not "increasing the pace" of, guidance.
FY 2026-2027 capex guidance raised to Rs.500 crore — up from the Rs.400 crore guided at the Q1 FY 2026-2027 call, citing strong momentum.
185 greenfield facilities added since FY23 — accelerating from 10 additions in FY23 to 37 in H1 FY27; management says new facilities attract strong footfalls from the first months.
Surgical-center mix shift — management's stated goal is to gravitate toward surgical centers given better throughput; surgical centers currently average Rs.75-80 lakh per month (stated on the Q2 FY 2026-2027 call).
Delhi NCR push — 5 greenfield centers commissioned in Q2 FY27 (Noida, Ghaziabad, Delhi) plus a 2-facility acquisition; network at ~15 facilities within 15 months of Q1 FY26 entry, with another 8-12 centers planned over the next 9-12 months (extending into FY 2027-2028).
Center planning runs 12-18 months ahead — ~100 candidate sites filtered to a standing goal of ~60 openings per year; groundwork for FY27 openings (site identification, lease signing) was largely completed in FY25.
South Delhi Bolt-On at Rs.55 Crores; FY25 Vintage Boosted by Punjab Deal
First acquisition in a while in Q2 FY27 — two centers acquired from Dr. Anshul Gupta (Greater Kailash, South Delhi and Loni, Ghaziabad) via a BTA; target delivered LTM revenue of Rs.13.5 crore and business EBITDA of Rs.7.16 crore.
Total consideration of Rs.55 crores — structured milestone-based with ~Rs.33 crores paid upfront and the balance payable over 4 years linked to milestones (management confirmation on the Q2 FY27 call).
M&A strategy remains predominantly greenfield — CEO Dr. Adil Agarwal said bolt-ons will be considered only at the right multiple and where they strategically fit newer markets, explicitly not in Chennai, Bangalore or Hyderabad; CBO Ashar Agarwal added that acquisitions with "stellar partners" should not be ignored by a company of this size.
FY25 vintage outperformance is acquisition-driven — CEO clarified the FY25 cohort's higher base is entirely due to one very large Punjab facility acquisition; excluding it, FY24 is the better-performing vintage. The Punjab acquisition contributed ~Rs.42 crore in H1 FY 2026-2027.
High-End Cataract at 30% of Volumes; Refractive Recovery Led by SMILE
~1,87,000 surgeries performed in H1 FY27 — up 19% YoY; cataract remained the largest contributor at ~73% of total surgeries, refractive at ~4.7%; cataract and refractive volumes each grew ~20% YoY.
High-end cataract reached ~30% of cataract volumes in Q2 FY27 — up from ~18% in FY24; management does not expect the mix to reach 50-60% and expects it to stabilize at 30-35% at least for the next few years, supported by rising disposable incomes and growing insurance penetration.
Lenticular (SMILE) procedures grew ~41% in Q2 FY27 — femto cataract grew ~26% (CFO Yashwant Venkat); new lenticular machines added in Pune, Cochin and Coimbatore; volume recovery driven by the market's shift from traditional LASIK to lenticular procedures.
PPP milestone — world's first PPP-capable department launched at the Chennai flagship, inaugurated by the Chief Minister of Tamil Nadu; 540+ PPP surgeries in H1 FY27 already exceed the full-FY26 volume of 500; management intends to take PPP across the network and globally.
Revenue mix (H1 FY27) — surgical services 66% of group revenue; diagnostics, consultations and other non-surgical treatments 12%; opticals and pharmacy 20%. Payer mix: 63% cash, 28% insurance/TPA, 9% government schemes.
COGS Held Near 21%; Rs.42 Crores Cumulative Startup Losses Quantified
Q2 FY27 COGS at 21.3% of revenue — CEO Dr. Adil Agarwal (initially citing 21.5% before correcting) said there was no significant movement in COGS relative to revenue growth; COGS has historically stayed in the 21–21.2% range, and management indicated ~21% is the "sweet spot" it wants to operate at (period unspecified).
Surgical lens consumption rose to ~12.6% of revenue in Q2 FY27 — flagged by analyst Shubh Kalra (Asit C. Mehta); management did not directly address the line item, responding only at the total COGS level.
Cumulative new-facility losses of ~Rs.42 crores over H1 FY 2026-2027 — CFO Yashwant Venkat, spanning the FY26 and FY27 cohorts: FY27 cohort ~Rs.18.2 crores, FY26 cohort ~Rs.20.12 crores.
Consultancy charges to doctors of ~Rs.96 crores — figure cited on the Q2 FY27 call, includes all new facilities and a very small number of doctors pre-hired for upcoming new centers.
New depreciation base confirmed at Rs.82-83 crores — per the CFO in Q2 FY 2026-2027.
Gross margin improved 50 bps YoY to 78.9% in H1 FY27 — gross profit Rs.1,014 crores, despite a richer surgical mix; doctor and employee costs broadly stable at 33.8% of total income, other expenses at 16.8%; finance costs of Rs.46 crores fell from 4.7% to 3.6% of total income.
Doctor attrition at ~14% — management cited a 14-15% range including trainees as of Q2 FY27, with senior-level surgeon attrition at less than ~1-2%; figures have held steady over the last 6 months with no material regional difference. Exact splits on fellowship retention and pipeline-vs-lateral surgeon sourcing were deferred.
Lens Margin Debate Premature to Assess; Merger Effective 01 Nov 2026
Regulatory risk on device/implant margins unresolved — asked by Harit Ahmed (Avendus Spark) whether court interventions on hospital drug markups could extend to intraocular lens margins, COO Rahul Agarwal said the government is trying to increase affordability and access of healthcare; with discussions ongoing between the Supreme Court and the government, it is "premature" for the company to comment on whether this is a risk or what the impact could be — management will comment only as developments fructify or reach a conclusion.
Merger scheme took effect on November 1, 2026 — CEO Dr. Adil Agarwal said the subsidiary will stop trading by November 17, 2026, and from November 18, 2026 onwards only one company — Agarwal Healthcare Limited — will be recorded, with all subsidiary shareholders receiving allocated shares in the holding company on that date.
Sun Pharma eye-drop halt: no impact on pharmacy business — responding to Shubh Kalra (Asit C. Mehta) on Sun Pharma's announced halt in production of certain eye drops on 30th October (reportedly quality-related, following an earlier ophthalmic recall), CEO said the company works with a wide range of products from different companies and Sun Pharma is not a big part of its pharmaceutical supply chain.
Regional growth (H1 FY27) — South 62% of revenue at Rs.790 crores (+24.6% YoY); West 15% at Rs.195 crores (+30% YoY) with 8 new surgical greenfields; North 9% at Rs.115 crores (+60% YoY, 36 facilities); East Rs.35 crores (+30% YoY) with a new leadership team in place. Africa operations grew 31.1% YoY, contributing ~10.4% of group revenue.
Growth levers (qualitative, no numeric targets) — management stated future growth will be driven by deepening presence in existing micro markets, expanding into new geographies, and accelerating adoption of advanced surgical procedures and technologies; new capex is directed at deepening presence in southern states (Tamil Nadu, Karnataka, Kerala, Andhra Pradesh, Telangana).
Outlook — management characterized H1 FY27 as a very strong half driven by operational discipline and consistent execution, positioning the company to carry momentum through the rest of FY27; break-evens achieved in many core-market centers support rollout confidence in existing and newer markets such as Delhi NCR and Mumbai.
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings